The PI3K pathway is a critical regulator of cell growth, survival, and proliferation, with PTEN acting as a key negative regulator by dephosphorylating PIP3. Mutations in PIK3CA and PTEN are common in human cancers, leading to uncontrolled PI3K signaling and tumor development. PTEN has additional functions beyond its phosphatase activity, including roles in the nucleus. The PI3K pathway is complex, involving feedback regulation and interactions with other signaling pathways. PTEN loss of function is associated with increased cancer risk, and its inactivation can occur through various mechanisms, including mutations, deletions, and epigenetic changes. PTEN haploinsufficiency may contribute to tumorigenesis in certain contexts. The PI3K pathway is a promising therapeutic target, but its complexity poses challenges in drug development. Inhibitors targeting PI3K, such as PI-103, show potential in cancer treatment. Feedback mechanisms within the PI3K pathway, including those involving mTOR, complicate therapeutic strategies. Understanding the regulation of PTEN and the PI3K pathway is essential for developing effective cancer therapies. The interplay between PTEN and other tumor suppressors, such as p53, highlights the complexity of cancer biology. Mouse models and in-depth studies of human tumors are crucial for elucidating the role of the PI3K pathway in cancer. The significance of the PI3K pathway in cancer underscores the need for further research to identify effective therapeutic strategies.The PI3K pathway is a critical regulator of cell growth, survival, and proliferation, with PTEN acting as a key negative regulator by dephosphorylating PIP3. Mutations in PIK3CA and PTEN are common in human cancers, leading to uncontrolled PI3K signaling and tumor development. PTEN has additional functions beyond its phosphatase activity, including roles in the nucleus. The PI3K pathway is complex, involving feedback regulation and interactions with other signaling pathways. PTEN loss of function is associated with increased cancer risk, and its inactivation can occur through various mechanisms, including mutations, deletions, and epigenetic changes. PTEN haploinsufficiency may contribute to tumorigenesis in certain contexts. The PI3K pathway is a promising therapeutic target, but its complexity poses challenges in drug development. Inhibitors targeting PI3K, such as PI-103, show potential in cancer treatment. Feedback mechanisms within the PI3K pathway, including those involving mTOR, complicate therapeutic strategies. Understanding the regulation of PTEN and the PI3K pathway is essential for developing effective cancer therapies. The interplay between PTEN and other tumor suppressors, such as p53, highlights the complexity of cancer biology. Mouse models and in-depth studies of human tumors are crucial for elucidating the role of the PI3K pathway in cancer. The significance of the PI3K pathway in cancer underscores the need for further research to identify effective therapeutic strategies.